SCA
NDRA icon

Sassicaia Capital Advisers’s ENDRA Life Sciences NDRA Stock Holding History

Sassicaia Capital Advisers’s Portfolio NDRA Stock Details NDRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-9
Closed -$1.55K – 27
2024
Q2 		$1.55K Buy
+9
New +$3.88K 0.01% 20

Other funds holding NDRA

VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Sassicaia Capital Advisers's NDRA Position: Q3 2024 in Review

Sassicaia Capital Advisers sold out of ENDRA Life Sciences (NDRA) in Q3 2024, closing a stake of 9 shares — an estimated $1.55K sold.

Sassicaia Capital Advisers first reported a position in NDRA in Q2 2024 and held it in 1 quarter. The position peaked at $1.55K in Q2 2024. 9 funds tracked by Wall St. Rank hold NDRA as of Q3 2024.

  • Sassicaia Capital Advisers reported no remaining ENDRA Life Sciences position as of Q3 2024 after selling out during the quarter.
  • Sassicaia Capital Advisers sold 9 ENDRA Life Sciences shares in Q3 2024, an estimated $1.55K.
  • Sassicaia Capital Advisers first reported a position in ENDRA Life Sciences in Q2 2024 and held it in 1 quarter.
  • Sassicaia Capital Advisers's ENDRA Life Sciences position peaked at $1.55K in Q2 2024.
  • 9 funds tracked by Wall St. Rank held ENDRA Life Sciences as of Q3 2024.

Based on Sassicaia Capital Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.